Pilot Study of Tamoxifen Treatment for Pre-Invasive Pancreatic Mucinous Cystic Neoplasms in Adults Not Scheduled for Immediate Surgery

What this Trial Is About

Researchers are studying pancreatic mucinous cystic neoplasm MCN, a condition that can lead to invasive pancreatic adenocarcinoma, mostly affecting women aged 40 to 70. Since current treatment involves surgery, this trial explores whether tamoxifen, an anti-hormonal drug, can help reduce or stabilize cysts and potentially delay the need for surgery. This pilot study aims to assess the feasibility of using tamoxifen for MCN treatment and to gather information to guide future trials. Participants will take tamoxifen 20 mg orally once daily for up to 24 weeks. This open-label study enrolls up to 15 people with pancreatic MCN who are not scheduled for immediate surgery. The study focuses on evaluating how well participants adhere to and tolerate the daily tamoxifen treatment over six months. During the study, participants will undergo magnetic resonance imaging MRI to monitor cyst changes and will be regularly assessed for treatment adherence and retention. The main outcomes measured include adherence to tamoxifen over six months and the cyst response over one year. Safety and participant retention will also be closely monitored, with the entire observation period lasting up to 12 months.

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection